Personalis Inc (PSNL) Stock Price, Quote & News

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 752 1300

Fax: 650 752 1301

Website: www.personalis.com

Address:

6600 Dumbarton Circle, Fremont, United States

Bulltrader988 Sep. 14 at 6:12 PM

$PSNL SCHEDULE 13D/A filled on 2025-09-12 Tempus AI, Inc. $TEM owns 12,718,800 shares = 14.3 % 👃👀 https://www.sec.gov/Archives/edgar/data/1527753/000164117225027202/xslSCHEDULE_13D_X01/primary_doc.xml

0 · Reply

ExNoose Sep. 13 at 8:49 AM

$PSNL Tempus can acquire shares of PSNL in open market, as long as they dont exceed 19.99% https://investors.personalis.com/node/10361/html

1 · Reply

MoneyGroupLLC Sep. 13 at 8:14 AM

Enter: $PSNL OCT 17 2025 $8 CALLS Buy in Price: $0.40 - $0.45 Take Profit: $0.56 Stop Bleeding: $0.35 ROI Potential: 40% Exit Within: 57 Minutes https://moneygroup.us/alerts

1 · Reply

E444 Sep. 12 at 2:22 PM

$PSNL only two days worth of progress wiped from a a market surge isn’t bad

0 · Reply

ExNoose Sep. 12 at 12:33 PM

$PSNL Just look at the money on the side lines... 7 Trillion. When that money ll search for yield...

0 · Reply

ExNoose Sep. 12 at 12:29 PM

$PSNL That biotech bear market will be one to remember. The squeeze that is coming, will be one to remember as well...

1 · Reply

M_Dixon Sep. 11 at 7:32 PM

$PSNL NXXT the closer we base to 2.00, the more violent the post-break follow-through

0 · Reply

ExNoose Sep. 11 at 7:18 PM

$PSNL If they release reimbursement news after hours today, i ll skip work and stay at home to watch the 1' candles.

2 · Reply

E444 Sep. 11 at 7:11 PM

$PSNL no dip? Really?

0 · Reply

LucienW Sep. 11 at 6:38 PM

$PSNL looks like we have reached the upper limit of the pre-reimbursement range bound

1 · Reply

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 3, 2025, 4:05 PM EDT - 10 days ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Aug 27, 2025, 4:01 PM EDT - 17 days ago

Personalis to Participate in Upcoming Investor Conferences

Aug 6, 2025, 8:11 AM EDT - 5 weeks ago

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

SMCI

Aug 5, 2025, 10:49 PM EDT - 5 weeks ago

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:01 PM EDT - 5 weeks ago

Personalis Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 7 weeks ago

Personalis to Announce Second Quarter 2025 Financial Results

Jul 18, 2025, 4:00 PM EDT - 2 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 9, 2025, 4:00 PM EDT - 2 months ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Jun 3, 2025, 4:00 PM EDT - 3 months ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 2, 2025, 4:00 PM EDT - 3 months ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

May 22, 2025, 6:00 AM EDT - 4 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 14, 2025, 4:01 PM EDT - 4 months ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 6, 2025, 8:41 PM EDT - 4 months ago

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 4 months ago

Personalis Reports First Quarter 2025 Financial Results

Apr 28, 2025, 5:00 PM EDT - 4 months ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 22, 2025, 4:01 PM EDT - 5 months ago

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 6:00 AM EDT - 5 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Mar 26, 2025, 4:01 PM EDT - 6 months ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 3, 2025, 6:00 AM EST - 6 months ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Feb 27, 2025, 7:40 PM EST - 7 months ago

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 7 months ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 4:21 PM EST - 7 months ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX GERN MRNA TEM

Feb 18, 2025, 4:01 PM EST - 7 months ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 14, 2025, 10:50 AM EST - 7 months ago

Exciting Technology At Personalis, But Profitability Eludes Them

Feb 13, 2025, 4:01 PM EST - 7 months ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Jan 28, 2025, 4:01 PM EST - 8 months ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 5:00 AM EST - 8 months ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 7, 2025, 4:01 PM EST - 8 months ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 9:00 AM EST - 9 months ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 16, 2024, 8:00 AM EST - 9 months ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Nov 20, 2024, 4:01 PM EST - 10 months ago

Personalis to Participate at Upcoming Investor Conferences

Nov 6, 2024, 8:11 PM EST - 11 months ago

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 11 months ago

Personalis Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 4:01 PM EST - 11 months ago

Personalis to Present at the Stifel 2024 Healthcare Conference

Oct 23, 2024, 4:01 PM EDT - 11 months ago

Personalis to Announce Third Quarter 2024 Financial Results

Sep 16, 2024, 9:00 AM EDT - 1 year ago

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Aug 18, 2024, 7:47 AM EDT - 1 year ago

Personalis: Resetting My Strategy Following The Q2 Beat

Aug 16, 2024, 8:30 AM EDT - 1 year ago

Personalis and Tempus Announce Expanded Collaboration

TEM

Aug 7, 2024, 11:09 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Personalis Reports Second Quarter 2024 Financial Results

Jul 31, 2024, 4:01 PM EDT - 1 year ago

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Jul 24, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Second Quarter 2024 Financial Results

Jun 18, 2024, 4:01 PM EDT - 1 year ago

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

Jun 13, 2024, 8:00 AM EDT - 1 year ago

Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call

Jun 4, 2024, 4:05 PM EDT - 1 year ago

ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring

May 31, 2024, 9:05 AM EDT - 1 year ago

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

May 22, 2024, 9:05 AM EDT - 1 year ago

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

May 22, 2024, 9:00 AM EDT - 1 year ago

Antares Bolsters Private Wealth Team with Three New Senior Appointments

KHC

May 8, 2024, 11:53 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript

Bulltrader988 Sep. 14 at 6:12 PM

0 · Reply

ExNoose Sep. 13 at 8:49 AM

$PSNL Tempus can acquire shares of PSNL in open market, as long as they dont exceed 19.99% https://investors.personalis.com/node/10361/html

1 · Reply

MoneyGroupLLC Sep. 13 at 8:14 AM

Enter: $PSNL OCT 17 2025 $8 CALLS Buy in Price: $0.40 - $0.45 Take Profit: $0.56 Stop Bleeding: $0.35 ROI Potential: 40% Exit Within: 57 Minutes https://moneygroup.us/alerts

1 · Reply

E444 Sep. 12 at 2:22 PM

$PSNL only two days worth of progress wiped from a a market surge isn’t bad

0 · Reply

ExNoose Sep. 12 at 12:33 PM

$PSNL Just look at the money on the side lines... 7 Trillion. When that money ll search for yield...

0 · Reply

ExNoose Sep. 12 at 12:29 PM

$PSNL That biotech bear market will be one to remember. The squeeze that is coming, will be one to remember as well...

1 · Reply

M_Dixon Sep. 11 at 7:32 PM

$PSNL NXXT the closer we base to 2.00, the more violent the post-break follow-through

0 · Reply

ExNoose Sep. 11 at 7:18 PM

$PSNL If they release reimbursement news after hours today, i ll skip work and stay at home to watch the 1' candles.

2 · Reply

E444 Sep. 11 at 7:11 PM

$PSNL no dip? Really?

0 · Reply

LucienW Sep. 11 at 6:38 PM

$PSNL looks like we have reached the upper limit of the pre-reimbursement range bound

1 · Reply

ExNoose Sep. 11 at 5:18 PM

$PSNL Stop the nonsense. Its running because all bios are running because of rate cut expectations. Nasdaq is underperforming today. Ai tech rally has been going on for years and we were at the bottom of the barrel.

1 · Reply